Angion Biomedica Corp. (NASDAQ:ANGN), a biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address fibrotic diseases, today announced participation in an upcoming investment conference.
Angion’s President and CEO, Dr. Jay Venkatesan, will participate in the Shareholder Equity Conference, held virtually. The presentation will be a fireside chat format and investors will have the opportunity to ask management questions during the live presentation. Details are as follows:
Shareholder Equity Conference (Virtual)
A webcast of the event will be accessible online by visiting the events and presentations page under the investors section of Angion’s website at https://ir.angion.com/events-presentations. The webcast will remain archived on Angion’s website for approximately 30 days.
About Angion Biomedica Corp.
Angion is committed to transforming the treatment paradigm for patients suffering from fibrotic diseases for which there are no approved medicines or where existing approved medicines have known limitations. Angion’s lead product candidate is ANG-3070, a highly-selective oral tyrosine kinase receptor inhibitor in development for the treatment of fibrotic kidney and lung diseases. Enrollment is ongoing in JUNIPER, a dose-finding Phase 2 trial of ANG-3070 in primary proteinuric kidney diseases (NCT04939116). Additionally, Angion has preclinical programs focused on rho kinase 2 (ROCK2) inhibition and CYP11B2 (aldosterone synthase) inhibition. For more information, please visit www.angion.com.
Contact
David D. Miller
Sr. Director of Communications & Investor Relations
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$7.33 |
| Daily Change: | -0.14 -1.87 |
| Daily Volume: | 38,267 |
| Market Cap: | US$79.040M |
December 12, 2024 November 13, 2024 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
